This study has highlighted that individuals with type 2 diabetes using daily insulin prefer rtCGM over traditional SMBG due to perceived health benefits, the facilitation of increased engagement with diabetes-related care, and the general acceptability of use. This evidence concerns the gene INS and type 2 diabetes mellitus.